Ahead of its impending financial Q1 results call, Towa disclosed its near-future plans and goals that are expected to see the company emerge out of Japan’s generic drugs crisis.
Ahead of Towa Pharmaceutical’s awaited financial first quarter results for the 2025 financial year appearing next week, Generics Bulletin has reviewed the firm’s recently published “Proactive” medium-term business plan to see the company’s path out of the Japanese generic drug crisis.
Towa’s sixth medium-term business plan charts the company’s path to 2026. Similarly to the firm’s fifth medium-term business plan, the...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
